Omental Chemotherapy Effects as a Prognostic Factor in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy and Delayed Primary Surgical Debulking-Reference-Cited by-同舟云学术

Omental Chemotherapy Effects as a Prognostic Factor in Ovarian Cancer Patients Treated With Neoadjuvant Chemotherapy and Delayed Primary Surgical Debulking

Published:2007-06-12 Issue:9 Volume:14 Page:2649-2653
ISSN:1068-9265
Container-title:Annals of Surgical Oncology
language:en
Short-container-title:Ann Surg Oncol

Author:

Le Tien,Williams Kona,Senterman Mary,Hopkins Laura,Faught Wylam,Fung-Kee-Fung M.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Surgery

Link

http://link.springer.com/content/pdf/10.1245/s10434-007-9460-2.pdf

Reference14 articles.

1. Barnholtz-Sloan JS, Schwartz AG, Qureshi F, et al. Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades. Am J Obstet Gynecol 2003;189:1120–7

2. McGuire V, Jesser CA, Whittemore AS. Survival among US women with invasive epithelial ovarian cancer. Gynecol Oncol 2002;84:399–403

3. Ferrandina G, Legge F, Salutari V, et al. Impact of pattern of recurrence on clinical outcome of ovarian cancer patients: clinical considerations. Eur J Cancer 2006;42:2296–302

4. Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer. Gynecol Oncol 2006;100:283–7

5. Chi DS, Franklin CC, Levine DA, et al. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach. Gynecol Oncol 2004;94:650–4

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. RAD51 Foci as a Biomarker Predictive of Platinum Chemotherapy Response in Ovarian Cancer;Clinical Cancer Research;2023-04-25

2. Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going?;Annals of Translational Medicine;2020-12

3. Prognostic factors of overall survival for patients with FIGO stage IIIc or IVa ovarian cancer treated with neo-adjuvant chemotherapy followed by interval debulking surgery: A multicenter cohort analysis from the FRANCOGYN study group;European Journal of Surgical Oncology;2020-09

4. Ovarian High-Grade Serous Carcinoma;Surgical Pathology Clinics;2019-06

5. Pathologic response to neoadjuvant chemotherapy in advanced ovarian cancer: utility of a scoring system to predict outcomes;International Journal of Gynecologic Cancer;2019-05-05